Ameriprise
KRSA

Ameriprise’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Ameriprise’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-320
Closed -$272K – 3769
2020
Q3 		$272K Buy
+320
New +$36.6K ﹤0.01% 3452

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise's KRSA Position: Q4 2020 in Review

Ameriprise sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q4 2020, closing a stake of 320 shares — an estimated $272K sold.

Ameriprise first reported a position in KRSA in Q3 2020 and held it in 1 quarter. The position peaked at $272K in Q3 2020. 70 funds tracked by Wall St. Rank hold KRSA as of Q4 2020.

  • Ameriprise reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Ameriprise sold 320 Korsana Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $272K.
  • Ameriprise first reported a position in Korsana Biosciences, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Ameriprise's Korsana Biosciences, Inc. Common Stock position peaked at $272K in Q3 2020.
  • 70 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2020.

Based on Ameriprise's 13F filing for Q4 2020, filed 12 Feb 2021.